Bibliography
- Paiva B, Gutierrez NC, Rosinol L, et al. High-risk cytogenetics and persistent minimal residual disease by multiparameter flow cytometry predict unsustained complete response after autologous stem cell transplantation in multiple myeloma. Blood 2012;119:687-91
- van de Donk NW, Lokhorst HM, Anderson KC, Richardson PG. How i treat plasma cell leukemia. Blood 2012;120:2376-89
- Kumar SK, Lee JH, Lahuerta JJ, et al. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study. Leukemia 2012;26:149-57
- Lacy MQ, Allred JB, Gertz MA, et al. Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of 2 dosing strategies in dual-refractory disease. Blood 2011;118:2970-5
- Leleu X, Attal M, Arnulf B, et al. Pomalidomide plus low-dose dexamethasone is active and well tolerated in bortezomib and lenalidomide-refractory multiple myeloma: intergroupe Francophone du Myelome 2009-02. Blood 2013;121:1968-75
- Dimopoulos MA, Lacy MQ, Moreau P, et al. Pomalidomide in combination with low-dose dexamethasone: demonstrates a significant progression free survival and overall survival advantage, in relapsed/refractory mm: a phase 3, multicenter, randomized, open-label study. ASH Annu Meet Abstr 2012;120:LBA-6
- Palumbo A, Larocca A, Montefusco V, et al. Pomalidomide cyclophosphamide and prednisone (pcp) treatment for relapsed/refractory multiple myeloma. ASH Annu Meet Abstr 2012;120:446
- Niesvizky R, Martin TG III, Bensinger W, et al. Phase Ib dose-escalation study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma. Clin.Cancer Res 2013;19(8):2248-56
- Jakubowiak AJ, Dytfeld D, Griffith KA, et al. A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma. Blood 2012;120:1801-9
- Sonneveld P, Asselbergs E, Zweegman S, et al. Carfilzomib combined with thalidomide and dexamethasone (ctd) is an highly effective induction and consolidation treatment in newly diagnosed patients with multiple myeloma (mm) who are transplant candidate. ASH Annu Meet Abstr 2012;120:333
- Richardson PG, Jagannath S, Moreau P, et al. A Phase 2 Study of Elotuzumab (elo) in combination with lenalidomide and low-dose dexamethasone (ld) in patients (pts) with relapsed/refractory multiple myeloma (r/r mm): updated results. ASH Annu Meet Abstr 2012;120:202
- Plesner T, Lokhorst H, Gimsing P, et al. Daratumumab, a CD38 monoclonal antibody in patients with multiple myeloma - data from a dose-escalation phase I/II study. ASH Annu Meet Abstr 2012;120:73
- van de Donk NW, Kamps S, Mutis T, Lokhorst HM. Monoclonal antibody-based therapy as a new treatment strategy in multiple myeloma. Leukemia 2012;26:199-213
- Berdeja JG, Hernandez-Ilizaliturri F, Chanan-Khan A, et al. Phase I study of lorvotuzumab mertansine (lm, imgn901) in combination with lenalidomide (len) and dexamethasone (dex) in patients with cd56-positive relapsed or relapsed/refractory multiple myeloma (mm). ASH Annu Meet Abstr 2012;120:728
- Keats JJ, Chesi M, Egan JB, et al. Clonal competition with alternating dominance in multiple myeloma. Blood 2012;120:1067-76